Cancer / Oncology/Breast cancer
Breast · type
Breast cancer
Clinical / Scientific
Breast carcinomas are molecularly heterogeneous. Intrinsic subtypes (luminal ER-driven, HER2-enriched, basal-like/triple-negative) differ in RTK dependence, DNA-repair load, immune infiltration and metabolic wiring. Hallmark programmes of proliferation, invasion and immune evasion are shared but not identical.
Molecular / histological subtypes
Core Biological Drivers
Estrogen-receptor transcription
ESR1-driven genomic signalling in luminal tumours.
HER2 amplification
ERBB2 amplification produces ligand-independent ERBB signalling.
PI3K/AKT/mTOR
PIK3CA mutation and PTEN loss are common, especially in luminal disease.
TP53 / DNA-repair stress
TP53 mutation and homologous-recombination defects concentrate in basal-like disease.
Hypoxia and angiogenesis
Disordered vasculature and support expansion and dissemination.
Immune escape
PD-L1 and myeloid suppression vary by subtype, highest in some triple-negative tumours.
Key Pathways
Scientific explanation
ERα (ESR1) drives a large fraction of breast cancers via genomic and non-genomic signalling. ESR1 mutations and growth-factor crosstalk contribute to endocrine resistance.
Scientific explanation
HER2/ERBB2 amplification or overexpression produces ligand-independent ERBB signalling, classically in a subset of breast and gastroesophageal cancers and rarely in colorectal cancer.
Scientific explanation
phosphorylates PIP2 to PIP3, recruiting . supports growth, survival, glucose uptake and mTORC1 input. Pathway activation is common via PIK3CA mutation, PTEN loss or -tyrosine- signalling.
Scientific explanation
mTORC1 integrates growth-factor and nutrient signals to drive protein synthesis, lipid synthesis and suppression. It sits downstream of PI3K/AKT and amino-acid sensing.
Scientific explanation
The RAS–RAF–MEK–ERK cascade transmits mitogenic RTK signals to programmes for proliferation and differentiation.
Scientific explanation
TP53 encodes a stress-responsive factor controlling cell-cycle arrest, and metabolic adaptation. Loss or mutation is among the most common cancer events.
Scientific explanation
Homologous-recombination defects (BRCA1/2 and related) create dependence on PARP-mediated repair. Mismatch-repair deficiency creates hypermutation and immune visibility.
Scientific explanation
Aerobic (Warburg metabolism) supports ATP, biomass and redox buffering even when oxygen is available. Hexokinase, PKM2 and lactate export are frequent nodes.
Scientific explanation
family ligands drive endothelial sprouting and vascular permeability, a canonical tumour axis.
Scientific explanation
PD-1 on T cells engaging PD-L1/PD-L2 restrains cytotoxic function. Tumour or myeloid PD-L1 is a canonical adaptive immune-evasion axis.
Scientific explanation
Epithelial–mesenchymal plasticity, driven by TWIST/SNAIL/ZEB and TGF-β/Wnt/Notch inputs, reduces adhesion and increases motility and stem-like features.
Scientific explanation
Stem-like programmes (Wnt, Notch, Hedgehog, ALDH, CD44) can support self-renewal, quiescence and therapy tolerance in a minority population.
Scientific explanation
Intrinsic and extrinsic apoptotic programmes remove damaged cells. Evasion of is a hallmark, via BCL-2 family imbalance, death- decoys, or p53 loss.
Pathway Convergence
Target → pathway → downstream effect → biological consequence. Shared intersections are mechanistic maps, not protocols.
Growth-factor signalling
Ligand or mutation-driven RTK input feeds PI3K/AKT and mTORC1, supporting anabolic growth. This is a map of signalling, not a treatment protocol.
Hypoxia to vessels
Low oxygen stabilizes HIF-1α, inducing VEGF and endothelial sprouting. Anti-angiogenic pharmacology intersects this axis but does not erase the tumour ecosystem.
Inflammatory survival
Chronic cytokine tone activates NF-κB and STAT3 transcriptional programmes that favour survival, invasion and sometimes immune evasion.
Energy stress
Energetic stress activates AMPK, which can restrain mTORC1. Biguanides and related tools map onto this axis in models.
Metabolic Vulnerabilities
Aerobic supports ATP, biomass and acidification even when oxygen is available. Extent varies by tumour and remains a vulnerability hypothesis rather than a uniform target.
Glutamine anaplerosis and nucleotide nitrogen demand are prominent in MYC-high and rapidly proliferating tumours. Dependence is heterogeneous.
/IGF crosstalk can reinforce signalling in obese or -resistant hosts.
Tumor Microenvironment
Disordered vasculature creates , HIF-1α stabilization, induction and immune-suppressive adenosine/lactate milieus.
Tumour-associated macrophages and myeloid-derived suppressor cells secrete cytokines that support invasion and blunt cytotoxic T cells.
Adipose-rich supplies adipokines and fatty acids.
Metastasis Module
, protease-mediated invasion, , circulating tumour-cell survival and organ-specific colonization form the metastatic cascade. Pre-metastatic niches and vascular permeability influence tropism.
Resistance Biology
Endocrine resistance includes ESR1 mutation, CDK–RB pathway alterations and RTK/ reactivation. HER2 resistance includes incomplete pathway shutdown and bypass RTKs. TNBC resistance often involves DNA-repair adaptation and drug efflux.
Cancer Stemness
Wnt, Notch, Hedgehog, ALDH and CD44-associated programmes can mark stem-like fractions with quiescence and therapy tolerance. These markers are not interchangeable across tumour types.
Mechanism-Based Adjunctive Strategies
Compounds appear only where a mechanistic overlap exists for this cancer. Evidence tiers are not equivalent. Nothing here is a treatment recommendation.
Target / Mechanism
Selective estrogen- modulator that antagonizes ERα-driven in breast epithelium while retaining partial activity in some other tissues.
Cancer relevance
Established SERM therapy for hormone--positive breast cancer according to labelled oncology practice. Tissue-specific / balance still applies.
Labelled endocrine therapy context. Convergence: Estrogen receptor, Apoptosis.
Target / Mechanism
Modest complex I inhibition raises AMP:ATP, activating and restraining hepatic and -linked anabolism. Direct antineoplastic efficacy is not established from that pharmacology alone.
Cancer relevance
activation and restraint provide a metabolic rationale in - and -linked tumours. Human data are mixed and do not establish metformin as cancer therapy.
Metabolic adjunctive research context. Convergence: AMPK, mTOR, Glycolysis.
Target / Mechanism
Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.
Cancer relevance
disruption can trigger mitotic stress and in cell and animal models. This is not an established oncology use.
Experimental antimitotic / microtubule stress. Convergence: Apoptosis, p53.
Target / Mechanism
Lysosomotropic agent that raises endosomal/autophagosomal pH, impairing flux. Combination trials in oncology have been mixed; blockade is not equivalent to proven benefit.
Cancer relevance
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Autophagy-modulation research combinations. Convergence: Autophagy.
Curcumin
Target / Mechanism
Polyphenol with promiscuous in-vitro NF-κB, and ROS effects. Bioavailability is poor; dish activity does not establish clinical anticancer efficacy.
Cancer relevance
In-vitro NF-κB/ effects are frequent. Poor bioavailability and absence of robust clinical anticancer efficacy keep this pathway-level.
Inflammatory-signalling dish models. Convergence: NF-κB, JAK/STAT.
Celecoxib
Target / Mechanism
Selective -2 reducing PGE2. Relevant to -associated epithelial neoplasia; cardiovascular risk and lack of broad anticancer approval constrain interpretation.
Cancer relevance
-2/PGE2 biology is relevant in some epithelial neoplasias. Cardiovascular risk and lack of broad anticancer approval apply. Do not equate polyp or biomarker studies with tumour cure.
Inflammation-associated epithelial neoplasia research. Convergence: COX / inflammatory signalling, Angiogenesis.
Statins (HMG-CoA reductase inhibitors)
Target / Mechanism
Inhibit HMG-CoA reductase, depleting mevalonate-pathway isoprenoids needed for RAS/RHO prenylation and some sterol-dependent growth programmes. Observational oncology signals are mixed and not a licence to treat cancer with statins.
Cancer relevance
Mevalonate-pathway blockade can affect prenylation of RAS-family GTPases. Observational human signals are mixed and confounding is substantial.
Mevalonate / prenylation mechanistic overlap. Convergence: RAS/RAF, Fatty-acid metabolism.
Propranolol
Target / Mechanism
Non-selective β-adrenergic . Adrenergic signalling can support and invasion in some tumours; selected clinical experiences (e.g. infantile haemangioma is established vascular biology, oncology uses are a different question).
Cancer relevance
β-adrenergic signalling can support and invasion in selected tumours. Oncology uses remain investigational except where a specific vascular indication is separately established.
Adrenergic / vascular adjunctive research. Convergence: Angiogenesis, Invasion.
Berberine
Target / Mechanism
Isoquinoline alkaloid that can inhibit complex I and activate in metabolic models, with additional -independent reports. Not an approved antineoplastic.
Cancer relevance
Complex I / pharmacology overlaps metformin-like energy stress in models. Bioavailability and lack of oncology indication keep this mechanistic.
Metabolic energy-stress hypothesis. Convergence: AMPK, mTOR, Mitochondrial oxidative phosphorylation.
Target / Mechanism
MT1/MT2 circadian with antioxidant chemistry. Adjunctive oncology hypotheses exist; circadian and redox effects should not be read as anticancer proof.
Cancer relevance
Circadian and antioxidant chemistry with adjunctive hypotheses. Not an antineoplastic standard.
Circadian / redox adjunctive research. Convergence: Oxidative stress, Apoptosis.
Omega-3 fatty acids
Target / Mechanism
EPA/DHA alter eicosanoid balance and membrane signalling. Cachexia and hypotheses exist; they are not cytotoxic oncology drugs.
Cancer relevance
Eicosanoid rebalancing and cachexia/ research. Not cytotoxic oncology.
Inflammation / cachexia supportive research. Convergence: COX / inflammatory signalling, Immune suppression.
EGCG
Target / Mechanism
Green-tea catechin with in-vitro effects on RTKs, epigenetic enzymes and redox. Clinical anticancer efficacy is not established.
Cancer relevance
Catechin effects on RTKs and redox in vitro. Clinical anticancer efficacy is not established.
RTK / redox dish models. Convergence: EGFR, PI3K/AKT.
Research Context
- Breast portraits. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. https://doi.org/10.1038/35021093
- HER2. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. https://doi.org/10.1126/science.3798106
- Hallmarks. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. https://doi.org/10.1016/j.cell.2011.02.013
- Metformin oncology. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2(9):778-790. https://doi.org/10.1158/2159-8290.CD-12-0263
- Tamoxifen. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205-213. https://doi.org/10.1038/nrd1031
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.